Details
Stereochemistry | ACHIRAL |
Molecular Formula | C28H26N2O5 |
Molecular Weight | 470.5164 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(COC2=CC=C(CO\N=C(/CCC(O)=O)C3=CC=CC=C3)C=C2)N=C(O1)C4=CC=CC=C4
InChI
InChIKey=ULVDFHLHKNJICZ-QCWLDUFUSA-N
InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+
Molecular Formula | C28H26N2O5 |
Molecular Weight | 470.5164 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Imiglitazar (also known as TAK-559) is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist patented by Japanese pharmaceutical company Takeda Chemical Industries for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance, and impaired glucose tolerance. Imiglitazar shows potent hypoglycemic and hypolipidemic activity and has been studied in clinical trials in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus. Unfortunately, Imiglitazar shows hepatotoxicity and has never been marketed.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00762190
TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:32:17 GMT 2023
by
admin
on
Sat Dec 16 17:32:17 GMT 2023
|
Record UNII |
7244710F59
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034214
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL592054
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
DTXSID00870280
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
DB12511
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
8460
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
9890879
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
7244710F59
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
C83791
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY | |||
|
250601-04-8
Created by
admin on Sat Dec 16 17:32:17 GMT 2023 , Edited by admin on Sat Dec 16 17:32:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|